Showing 105,021 - 105,040 results of 173,044 for search '(( 10 ((we decrease) OR (mean decrease)) ) OR ( 5 ((nn decrease) OR (a decrease)) ))', query time: 2.15s Refine Results
  1. 105021
  2. 105022
  3. 105023
  4. 105024

    Table1_Molecular subtyping of acute myeloid leukemia through ferroptosis signatures predicts prognosis and deciphers the immune microenvironment.XLS by Denggang Fu (5082062)

    Published 2023
    “…<p>Acute myeloid leukemia (AML) is one of the most aggressive hematological malignancies with a low 5-year survival rate and high rate of relapse. …”
  5. 105025

    Image3_Molecular subtyping of acute myeloid leukemia through ferroptosis signatures predicts prognosis and deciphers the immune microenvironment.TIF by Denggang Fu (5082062)

    Published 2023
    “…<p>Acute myeloid leukemia (AML) is one of the most aggressive hematological malignancies with a low 5-year survival rate and high rate of relapse. …”
  6. 105026

    Image1_Molecular subtyping of acute myeloid leukemia through ferroptosis signatures predicts prognosis and deciphers the immune microenvironment.TIF by Denggang Fu (5082062)

    Published 2023
    “…<p>Acute myeloid leukemia (AML) is one of the most aggressive hematological malignancies with a low 5-year survival rate and high rate of relapse. …”
  7. 105027

    Table2_Molecular subtyping of acute myeloid leukemia through ferroptosis signatures predicts prognosis and deciphers the immune microenvironment.XLSX by Denggang Fu (5082062)

    Published 2023
    “…<p>Acute myeloid leukemia (AML) is one of the most aggressive hematological malignancies with a low 5-year survival rate and high rate of relapse. …”
  8. 105028

    Image2_Molecular subtyping of acute myeloid leukemia through ferroptosis signatures predicts prognosis and deciphers the immune microenvironment.TIF by Denggang Fu (5082062)

    Published 2023
    “…<p>Acute myeloid leukemia (AML) is one of the most aggressive hematological malignancies with a low 5-year survival rate and high rate of relapse. …”
  9. 105029
  10. 105030

    <i>Dnmt3L</i> haploinsufficiency resulted in altered expression of the <i>Dnmt3L</i> splice variants. by Natasha M. Zamudio (225855)

    Published 2011
    “…Black bars  =  wildtype, white bars  =  heterozygous, n = 3 biological replicates (10 mice/replicate). Results are presented as means ± SEM. …”
  11. 105031

    Muscle strength and quality of life in patients with childhood cancer at early phase of primary treatment by Anne Deisenroth (3188382)

    Published 2016
    “…Forty children and adolescents aged 5–18 years (mean: 11.39 ± 4.08 years) with different types of childhood cancer were enrolled. …”
  12. 105032
  13. 105033
  14. 105034

    The Non-Classical MAP Kinase ERK3 Controls T Cell Activation by Miriam Marquis (515431)

    Published 2014
    “…Moreover, ERK3 protein is phosphorylated and associates with MK5 in activated primary T cells. We show that ERK3-deficient T cells have a decreased proliferation rate and are impaired in cytokine secretion following <i>in vitro</i> stimulation with low dose of anti-CD3 antibodies. …”
  15. 105035
  16. 105036
  17. 105037
  18. 105038
  19. 105039
  20. 105040